Skip to main content
. 2021 Apr 19;21(9):1257–1270. doi: 10.1016/S1473-3099(21)00147-X

Table 2.

Participant demographic characteristics (full analysis set) per treatment group for participants in the two-dose cohort

Low-dose plus AF03 group (n=28) Low-dose plus AS03 group (n=82) High-dose plus AF03 group (n=27) High-dose plus AS03 group (n=85) High-dose plus unadjuvanted group (n=18) Placebo group (n=29)
Aged 18–49 years
Sex .. .. .. .. .. ..
Female 9/18 (50%) 25/54 (46%) 11/17 (65%) 23/54 (43%) 10/18 (56%) 8/18 (44%)
Male 9/18 (50%) 29/54 (54%) 6/17 (35%) 31/54 (57%) 8/18 (44%) 10/18 (56%)
Age, years 35·3 (8·67) 33·7 (8·99) 32·5 (9·12) 34·9 (8·77) 34·8 (10·2) 32·0 (8·41)
Race or ethnicity .. .. .. .. .. ..
White 15/18 (83%) 46/54 (85%) 16/17 (94%) 48/54 (89%) 16/18 (89%) 16/18 (89%)
Asian 2/18 (11%) 4/54 (7%) 0/17 4/54 (7%) 1/18 (6%) 1/18 (6%)
Black or African American 1/18 (6%) 4/54 (7%) 1/17 (6%) 2/54 (4%) 1/18 (6%) 1/18 (6%)
American Indian or Alaska Native 0 0 0 0 0 0
Hispanic or Latino 4/18 (22%) 9/54 (17%) 2/17 (12%) 6/54 (11%) 3/18 (17%) 3/18 (17%)
Aged 50 years or older
Sex .. .. .. .. .. ..
Female 5/10 (50%) 11/28 (39%) 7/10 (70%) 21/31 (68%) NA 6/11 (55%)
Male 5/10 (50%) 17/28 (61%) 3/10 (30%) 10/31 (32%) NA 5/11 (45%)
Age, years 58·8 (7·69) 59·8 (6·53) 58·7 (7·92) 61·7 (7·86) NA 61·5 (4·41)
Race or ethnicity .. .. .. .. .. ..
White 9/10 (90%) 24/28 (86%) 9/10 (90%) 30/31 (97%) NA 10/11 (91%)
Asian 1/10 (10%) 3/28 (11%) 0 0 NA 0
Black or African American 0 0 0 1/31 (3%) NA 1/11 (9%)
American Indian or Alaska Native 0 1/28 (4%) 0 0 NA 0
Multiple 0 0 1/10 (10%) 0 NA 0
Hispanic or Latino 0 2/28 (7%) 1/10 (10%) 3/31 (10%) NA 0

Data are n/N (%) or mean (SD). NA=not applicable.